Has Anusiyanthan Mariampillai, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,414 in general payments to Anusiyanthan Mariampillai, MD across 50 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anusiyanthan Mariampillai, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anusiyanthan Mariampillai, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anusiyanthan Mariampillai, MD

Hematology & Oncology · Anchorage, AKNPI 1518221977

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations.

$4,414in general payments, 2019–2025

Across 50 payments — averaging $88.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$976
AstraZeneca$968
Daiichi Sankyo Inc.$674
Merck$224
Johnson & Johnson$174
Seagen Inc.$170
plus $1K from 15 others

What the payments were for

Food & beverage$4,28397%
Education$1313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	11	$976
AstraZeneca	9	$968
Daiichi Sankyo Inc.	8	$674
Merck	2	$224
Johnson & Johnson(2 entities)	2	$174
Seagen Inc.	2	$170
Genentech USA, Inc.	1	$127
G1 Therapeutics, Inc.	1	$125
Pfizer	1	$125
Agios Pharmaceuticals, Inc.	1	$120
Rigel Pharmaceuticals, Inc.	2	$120
Genmab U.S., Inc.	1	$115
Janssen Scientific Affairs, LLC	1	$105
Puma Biotechnology, Inc.	1	$100
Springworks Therapeutics, Inc.	1	$90
Karyopharm Therapeutics Inc.	1	$85
Bristol Myers Squibb	1	$44
Bayer	1	$25
Mirati Therapeutics, Inc.	1	$21
Helsinn Therapeutics (U.S.), Inc.	1	$15
Amgen	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$57,089

Medicare patients

130

Services billed

447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VerzenioAbemaciclib	11	$159,148
NinlaroIxazomib Citrate	12	$146,253
Atovaquone	11	$4,148
Tramadol Hcl ErTramadol Hcl	11	$756
Metoprolol Succinate	21	$234
Ondansetron OdtOndansetron	16	$212
Gabapentin	15	$176
Oxycodone Hcl	19	$164
Dexamethasone	29	$150
Acyclovir	12	$101
Omeprazole	15	$92
Tamsulosin Hcl	11	$79
LoperamideLoperamide Hcl	13	$73
Prednisone	16	$62
Tramadol Hcl	14	$42

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Anchorage

Steven LiuAnchorage$35K
Max RabinowitzAnchorage$14K
Mary KlixAnchorage$13K
Mary StewartAnchorage$9K
Kendal WebbAnchorage$8K
Natalie WallaceAnchorage$8K
Shannon SmileyAnchorage$6K
Charles BuessAnchorage$5K
Theodore KimAnchorage$2K
Ellen ChirichellaAnchorage$1K

See the full list for Alaska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →